SAVE随机对照试验中单次CT结肠成像或两年一次粪便免疫化学检测筛查后结直肠癌与进展期腺瘤的发生情况
本文为SAVE随机对照试验的二次分析,纳入54-65岁参与者,随机接受单次CT结肠成像或三次两年一次粪便免疫化学检测筛查。随访至2021年12月31日(平均8.4年),两组结直肠癌发病率无统计学显著差异(校正HR 0.73,95%CI 0.36-1.47,P=0.38),CTC组进展期腺瘤发病率持续显著高于FIT组(校正HR 1.46,95%CI 1.11-1.92,P=0.007)。作者认为5年CTC筛查间隔是合适的,且可能相对于FIT筛查与更早诊断相关。
要点
- CTC组5年内仅1例间期结直肠癌,此后未再检出结直肠癌。
- 两组结直肠癌发病率无统计学显著差异(校正HR 0.73,95%CI 0.36-1.47,P=0.38)。
- CTC组进展期腺瘤发病率持续显著高于FIT组(校正HR 1.46,95%CI 1.11-1.92,P=0.007)。
核心结论
- 5年CTC筛查间隔是合适的,且可能相对于FIT筛查与更早诊断相关。
研究设计与样本
- SAVE随机对照试验的二次分析,2012年3月至2018年3月开展,14 981名54-65岁参与者随机分配至单次CTC检查组或三次两年一次FIT筛查组。
诊断标准与关键数值
- 结直肠癌发病率比较采用校正年龄、性别和社会经济状态的Cox回归模型,校正HR 0.73(95%CI 0.36-1.47),P=0.38。
- 进展期腺瘤发病率比较采用校正年龄、性别和社会经济状态的Cox回归模型,校正HR 1.46(95%CI 1.11-1.92),P=0.007。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background A 5-year screening interval for CT colonography (CTC) and a 2-year screening interval for fecal immunochemical tests (FITs) have been recommended on the basis of the natural history of colorectal cancer (CRC). Purpose To assess whether the recommended 5-year interval for screening CTC is appropriate and whether CTC is associated with earlier diagnosis relative to biennial FIT screening. Materials and Methods This secondary analysis of the SAVE randomized controlled trial was conducted between March 2012 and March 2018; 14 981 participants aged 54-65 years were randomly assigned to groups undergoing a single CTC examination or three biennial FITs for CRC screening. After the trial period ended, all participants aged younger than 70 years were invited to undergo biennial FIT. The incidence rates of CRC and advanced adenoma (AdA) until December 31, 2021 (mean, 8.4 years of follow-up), in the 1286 participants who underwent CTC and 6027 participants who underwent at least one trial FIT were compared using Cox regression models adjusted for age, sex, and socioeconomic status. Results In the CTC arm, one interval CRC was observed during the 5 years following CTC, and no cancers were detected thereafter. Overall, nine CRC cases were diagnosed in the CTC arm and 58 in the FIT arm, with no statistically significant difference in CRC incidence rates between the two groups (adjusted hazard ratio, 0.73 [95% CI: 0.36, 1.47]; P = .38). All stage IV CRCs (n = 7) occurred in the FIT arm. By the end of follow-up, the CTC arm showed a persistently and significantly higher incidence rate of AdA compared with the FIT arm (adjusted hazard ratio, 1.46 [95% CI: 1.11, 1.92]; P = .007). Conclusion The 5-year interval for screening CTC is appropriate and might be associated with earlier diagnosis relative to FIT screening. Clinical trial registration no. NCT01651624 © RSNA, 2025 See also the editorial by Pietryga and Kim in this issue.
引用
- Puliti D, Sali L, Mascalchi M, et al. Colorectal Cancer and Advanced Adenoma after Single CT Colonography or Biennial FIT Screening in the SAVE Randomized Controlled Trial. Radiology. 2025. PMID: 41025989. doi:10.1148/radiol.250091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。